JNJ logo
Johnson & Johnson
JNJ
270.88 (0.62%) 1.69
Market cap
$652.79(B)
Earnings date
Oct-13-2026
Category
Sector
Health Care
Industry
Pharmaceuticals
Johnson & Johnson together with its subsidiaries engages in the research and development manufacture and sale of a range of products in the healthcare field worldwide. It operates in two segments Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas such as oncology immunology neuroscience pulmonary hypertension infectious diseases and cardiovascular and metabolism distributed through retailers wholesalers distributors hospitals and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery orthopedic cardiovascular and vision fields distributed through wholesalers hospitals and retailers and used in the professional fields by physicians nurses hospitals eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction trauma spine sports related injuries and others as well as open laparoscopic and robotic surgical procedures; instrumentation energy devices stapling systems wound closure biosurgery products and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick New Jersey.
EV: $694.79(B)
Total Equity: $84.97(B)
Debt/Equity: 0.58
Dividend/share: $5.2
Div. yield: 1.93%
P/E: 30.99
Forward P/E: 24.45
P/FCF: 29.32
P/S: 6.66
P/B: 7.68
EPS: $8.7
EPS (fwd): $11.1
FCF/share: $9.2
Revenue/share: $40.7
Book value/share: $35.3
ROIC: 21.7%
ROA: 13.5%
ROE: 33.6%
Margins: Gross | Op. | Net
68.1% | 26.2% | 21.5%
0.0%of Portfolio
My holdings
Day change
Total change
PEvaluation
12%
$239
Valuation summary
Min
Max
Average
Median
Valuation comparison
Current price$271
Quality checklist score
6/8
Based on your selected metrics.
5Y Shares Out Change < 0% ROIC > 10% Debt/Equity < 1 Current Ratio > 1 Net Margin > 10% Est. EPS Growth > 5%
Quick Ratio > 1 Past Net Income CAGR > 0%

TTM Financials

Income (TTM)

RevenueGrossNet
Revenue$97.93(B)
Gross profit$66.73(B)
EBITDA$34.87(B)
Net income$21.04(B)
Gross margin68.1%
Operating margin26.2%
Net margin21.5%
Shares outstanding2.41(B)

Balance sheet

Cash & ST inv.Other ST assetsLong term assetsCurrent liabilitiesLong term debtOther LT liabilitiesEquity
Total assets$201.06(B)
Current assets$59.77(B)
Total liabilities$116.09(B)
Current liabilities$54.90(B)
Cash & Short-term inv.$20.76(B)
Long-term debt$37.34(B)
Total intangibles$96.71(B)
PP&E$23.58(B)

Cash flow (TTM)

CFOCFICFF
FCF$22.24(B)
CapEx$-5.36(B)
Dividends paid$-12.62(B)
Stock issued$4.39(B)
Stock repurchased$-8.07(B)
Stock-based comp.$1.41(B)
Debt issued$18.38(B)
Debt repaid$-19.95(B)

Per share data (TTM)

Price
Price
$271
Income
Revenue
$40.76.7x|15.0%
Gross profit
$27.79.8x|10.2%
Earnings (EPS)
$8.7431.0x|3.2%
Cash flow
FCF
$9.2429.3x|3.4%
Stock-based comp.
$0.59461.7x|0.2%
CapEx
$2.23121.7x|0.8%
Dividend
$5.2451.7x|1.9%
Balance sheet
Total assets
$83.43.2x|30.8%
Total liabilities
$48.25.6x|17.8%
Book value
$35.37.7x|13.0%
Cash & ST inv.
$8.6131.4x|3.2%
Debt
$15.517.5x|5.7%
Forward earnings
EPS FY+1
$11.124.4x|4.1%
EPS FY+2
$12.421.8x|4.6%
EPS FY+3
$15.317.7x|5.7%
EPS FY+4
$18.115.0x|6.7%
EPS FY+5
$20.613.1x|7.6%
Forward FCF
FCF FY+1
$9.9827.1x|3.7%
FCF FY+2
$11.324.1x|4.2%
FCF FY+3
$12.421.8x|4.6%
FCF FY+4
$14.019.4x|5.2%
FCF FY+5
$14.518.6x|5.4%

Summary

JNJ Valuation & Price Targets

Favorite Valuation Methods

PEvaluation
Analyst targets
DCF (2-stage)

More Valuation Methods

DCF (simple)
DCF (exit mult.)
DDM
EPS growth
Revenue growth
Peter Lynch FV
Graham No.

PEvaluation

CURRENT PRICE
$271
12% Overvalued
BEAR
BASE
BULL
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+111.011.111.25
FY+211.312.413.55
FY+315.115.315.52
FY+418.018.118.12
FY+520.320.621.02

Analyst Price Targets

CURRENT PRICE
$271
4% Undervalued
BEAR
BASE
BULL

Analyst Recommendations

Strong Buy5
Buy11
Hold6
Sell1
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
Low
Mid
High
Terminal Growth Rate
Low
Mid
High
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
Low
Mid
High
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
Low
Mid
High
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Low
Mid
High
Final Growth Rate
Low
Mid
High
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
Low
Mid
High
Final P/E
Low
Mid
High
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
Low
Mid
High
Final Net Margin
Low
Mid
High
Final P/E Ratio
Low
Mid
High
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate
Low
Mid
High

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Low
Mid
High
Government Bond Rate

Growth Estimates

Revenue

CAGR7.5%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$97.93(B)
FY+1
5
3%
$101.28(B)
FY+2
5
8%
$109.07(B)
FY+3
2
9%
$118.94(B)
FY+4
2
9%
$129.61(B)
FY+5
2
8%
$140.46(B)

Net Income

CAGR19.0%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$21.04(B)
FY+1
4
28%
$26.98(B)
FY+2
4
11%
$29.98(B)
FY+3
2
24%
$37.28(B)
FY+4
2
18%
$43.88(B)
FY+5
2
14%
$50.21(B)

EPS

CAGR18.8%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$8.74
FY+1
5
27%
$11.08
FY+2
5
12%
$12.45
FY+3
2
23%
$15.34
FY+4
2
18%
$18.05
FY+5
2
14%
$20.64

FCF per share

CAGR9.5%
TTMFY+1FY+2FY+3FY+4FY+5
TTM
$9.24
FY+1
2
8%
$9.98
FY+2
2
13%
$11.26
FY+3
1
11%
$12.44
FY+4
1
12%
$13.99
FY+5
1
4%
$14.53

Historical Financials (in USD)

Income(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.020.0(B)40.0(B)60.0(B)80.0(B)
Revenue Operating Income Net IncomeCOGSGross ProfitTotal OpEx.R&DSG&AInterest ExpenseInterest IncomeOther Non-operating IncomePre-tax incomeIncome tax
Cash flow(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.05.0(B)10.0(B)15.0(B)20.0(B)
Stock-based Comp. FCFCFONet IncomeD&AChange in Working CapitalCFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.050.0(B)100.0(B)150.0(B)
Total Assets Total LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EIntangible AssetsGoodwillCurrent liabilitiesShort-Term DebtAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Per share data(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.02.04.06.08.010.012.0
EPS (Basic) FCF/Share Dividend/ShareEPS (Diluted)Book value/ShareCash & ST inv./ShareDebt/Share
Ratios(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.05.010.015.020.025.0
P/E P/S EV/EarningsP/FCFP/BDebt/EquityPayout ratio
Margins(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%20%40%60%
Net Income Margin Operating Margin Gross MarginEBITDA Margin
Returns(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0%5%10%15%20%25%30%
ROIC ROAROCEROE
Shares outstanding(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0500.0(M)1.0(B)1.5(B)2.0(B)2.5(B)
Shares (Basic)Shares (Diluted)
Market Cap.(show more...)
Q3'20 (TTM)Q3'21 (TTM)Q3'22 (TTM)Q3'23 (TTM)Q3'24 (TTM)Q3'25 (TTM)0.0100.0(B)200.0(B)300.0(B)400.0(B)
Market Cap.

KPIs

Revenue By Geography(show more...)
3/20246/20249/202412/20243/20256/20259/202512/20253/20266/2026
Western Hemisphere Excluding US Asia Pacific and Africa United States Europe
Revenue By Segment(show more...)
3/20246/20249/202412/20243/20256/20259/202512/20253/20266/2026
Medtech Pharmaceutical Consumer Health

JNJ vs Peers

Similar Companies

Ownership

Major holders

*Excludes indirect insider ownership

Insiders: 0.05%
Institutions: 76.73%
Other: 23.22%

Institutional ownership

8.80% Blackrock Inc.6.52% Vanguard Capital Manag...5.55% State Street Corporati...2.67% Vanguard Portfolio Man...2.45% Geode Capital Manageme...2.42% JPMORGAN CHASE & CO1.86% Morgan Stanley1.32% NORGES BANK1.31% State Farm Mutual Auto...1.19% Northern Trust Corpora...42.64% Others

Trading Summary

In the past year, insiders have sold a net of $154.60(M).

Total insider buys: $257688
Total insider sells: $154.85(M)

In the past year, Congress members have bought a net of $16001.

Total congressional buys (avg): $104505
Total congressional sells (avg): $88504

Based on the reported ranges: buys $24010–$185000, sells $22008–$155000.

Insider transactions

$0.002026-10$0.00
$9.23(M)2026-09$0.00
$52.76(M)2026-08$0.00
$5.79(M)2026-07$0.00
$2.41(M)2026-06$0.00
$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$58.35(M)2026-02$0.00
$22.12(M)2026-01$0.00
$0.002025-12$0.00
$0.002025-11$257688
$4.19(M)2025-10$0.00
DateSharesTotal ($)Price ($)NameTitle
Grant2026-09-0233,5974,871,389145.0SCHMID TIMOTHYOfficer
Sell2026-09-0233,5979,230,440274.7SCHMID TIMOTHYOfficer
Grant2026-08-1715,0001,735,050115.7TAUBERT JENNIFER LOfficer
Sell2026-08-1715,0003,950,400263.4TAUBERT JENNIFER LOfficer
Grant2026-08-13123,29114,261,070115.7DUATO JOAQUIN BOIXChief Executive Officer
Sell2026-08-13123,29132,199,927261.2DUATO JOAQUIN BOIXChief Executive Officer
Grant2026-08-069,3441,232,847131.9FORMINARD ELIZABETHOfficer
Sell2026-08-0615,9184,090,960257.0FORMINARD ELIZABETHOfficer
Sell2026-08-0548,48012,515,010258.1DUATO JOAQUIN BOIXChief Executive Officer
Grant2026-07-2023,0543,014,701130.8BROADHURST VANESSAOfficer
Sell2026-07-2023,0545,792,686251.3BROADHURST VANESSAOfficer
Grant2026-06-1110,0001,156,700115.7WENGEL KATHRYN EChief Technology Officer
Sell2026-06-1110,0002,411,500241.2WENGEL KATHRYN EChief Technology Officer
Grant2026-02-274,075471,355115.7DECKER ROBERT JOfficer
Sell2026-02-274,0751,010,070247.9DECKER ROBERT JOfficer
Sell2026-02-201,322324,763245.7SCHMID TIMOTHYOfficer
Grant2026-02-1829,5542,741,33592.8SCHMID TIMOTHYOfficer
Sell2026-02-1822,6235,527,506244.3SCHMID TIMOTHYOfficer
Grant2026-02-1773,14010,202,710139.5SWANSON JAMES DChief Technology Officer
Grant2026-02-17107,7848,193,22376.0WOLK JOSEPH JChief Financial Officer
Grant2026-02-1754,8448,103,281147.8REED JOHN COfficer
Sell2026-02-176,1971,508,288243.4BROADHURST VANESSAOfficer
Sell2026-02-1762,08015,109,759243.4SWANSON JAMES DChief Technology Officer
Sell2026-02-1789,65421,767,827242.8WOLK JOSEPH JChief Financial Officer
Sell2026-02-1753,93113,105,233243.0REED JOHN COfficer
Grant2026-02-0615,5711,586,218101.9SCHMID TIMOTHYOfficer
Grant2026-02-065,625573,019101.9MULHOLLAND KRISTENOfficer
Grant2026-02-0638,9453,967,327101.9WENGEL KATHRYN EChief Technology Officer
Grant2026-02-058,9211,155,359129.5FORMINARD ELIZABETHOfficer
Sell2026-01-26100,00022,122,893221.2DUATO JOAQUIN BOIXChief Executive Officer
Buy2025-11-261,250257,688206.2MORIKIS JOHN GDirector
Grant2025-10-1721,7213,430,180157.9REED JOHN COfficer
Sell2025-10-1721,7214,185,793192.7REED JOHN COfficer

Congressional trading

$0.002026-10$0.00
$0.002026-09$0.00
$0.002026-08$0.00
$0.002026-07$0.00
$0.002026-06$0.00
$0.002026-05$0.00
$0.002026-04$0.00
$0.002026-03$0.00
$0.002026-02$0.00
$0.002026-01$0.00
$80012025-12$8001
$405012025-11$40501
$320022025-10$48003
DatePoliticianPartyChamberAmount ($)
Sell2025-12-18Julie JohnsonDHouse$1,001 - $15,000
Buy2025-12-09Lloyd DoggettDHouse$1,001 - $15,000
Sell2025-11-20Thomas H. Kean, Jr.RHouse$15,001 - $50,000
Sell2025-11-13Julie JohnsonDHouse$1,001 - $15,000
Buy2025-11-07Ro KhannaDHouse$15,001 - $50,000
Buy2025-11-05Richard McCormickRHouse$1,001 - $15,000
Sell2025-10-31Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Buy2025-10-30Ro KhannaDHouse$1,001 - $15,000
Buy2025-10-30Ro KhannaDHouse$1,001 - $15,000
Buy2025-10-30Ro KhannaDHouse$1,001 - $15,000
Sell2025-10-30Lisa C. McClainRHouse$1,001 - $15,000
Sell2025-10-10Jared MoskowitzDHouse$1,001 - $15,000
Sell2025-10-10Jared MoskowitzDHouse$1,001 - $15,000
Buy2025-09-29Ro KhannaDHouse$1,001 - $15,000
Sell2025-09-23Val T. HoyleDHouse$1,001 - $15,000

Tools

Dividend Income

Investment Amount
Dividend Yield
What is the Dividend Income Calculator?

The Dividend Income Calculator helps you estimate the yearly, quarterly, monthly, and daily income of your investments.

How to Use This Calculator?

Enter the dividend yield and the invested amount. Optionally, preload stock data to automatically fetch the dividend yield.

Required Investment

Dividend Yield
Desired Yearly Payout
Desired Quarterly Payout
Desired Monthly Payout
What is the Required Investment Calculator?

The Required Investment Calculator helps you determine the amount of money you need to invest in a stock to achieve a desired dividend.

How to Use This Calculator?

Enter the dividend yield and your desired dividend income. Optionally, preload stock data to automatically fetch the dividend yield.

Future Dividend Yield

Base Dividend
Current Price
Number of Years
Dividend Growth Rate
What is the Future Yield Calculator?

The Future Yield Calculator helps you estimate the future dividend yield of a stock based on its current dividend, price, and expected dividend growth rate.

How to Use This Calculator?

Enter the base dividend, current price, number of years, and dividend growth rate. Optionally, preload stock data to automatically fetch the dividend and price. The calculator will display the current yield and the projected future yield.

Future Dividend Income

Base Dividend
Number of Years
Dividend Growth Rate
What is the Future Dividend Income Calculator?

The Future Dividend Income Calculator helps you estimate the future dividend income from your investments based on the current dividend yield and expected growth rate.

How to Use This Calculator?

Enter the current dividend yield, expected growth rate, and investment duration. Optionally, preload stock data to automatically fetch the dividend yield.